Iron deficiency (ID) is the most common nutritional deficiency in children & reportedly 3x more common than iron-deficiency anemia, but does not always develop into anemia.
Neonates & children may have delayed growth & development; adolescents may show decrements of learning such as behavioral abnormalities.
Iron-deficiency anemia is the most advanced stage of iron deficiency resulted from a protracted imbalance between iron intake & demand.
Characterized by low hemoglobin & hematocrit levels, reduction or depletion of iron stores, low serum iron levels & decreased transferrin saturation.
A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.